 | ||||||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
NovalarSan Diego-based Novalar Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company. The company’s initial product offering, NV-101 a local anesthetic reversal agent, was well tolerated and met the primary and secondary endpoints of two Phase 3 clinical studies and a Phase 2 pediatric study. The company is now focused on the execution of the commercialization plan for the US launch of the only local anesthetic reversal agent.
February 27, 2009 Novalar Announces the Launch of OraVerse™ the First Dental Anesthesia Reversal Agent June 19, 2007 NOVALAR announces acceptance of NV-101 New Drug Application for filing by FDA |
|
|
|
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG |
||||||||||||||||||||||||||||||||||
current news
Daniel Bertholet
Sven Lingjaerde